ANCA Testing and Treatment Decisions in ANCA-Associated Vasculitis

Key Evidence on ANCA Testing

The EULAR/ERA-EDTA guidelines recommend that structured clinical assessment, rather than ANCA testing, should inform decisions on changes in treatment in patients with ANCA-associated vasculitis (AAV), regardless of corticosteroid exposure 1, 2
ANCA levels do not reliably predict disease activity or relapse in AAV patients, and treatment changes should not be based on ANCA testing alone 1, 2
A negative ANCA result does not exclude active AAV in the appropriate clinical context, according to the EULAR/ERA-EDTA guidelines 1, 3

For new diagnosis, ANCA testing should be performed using high-quality antigen-specific assays (ELISA for PR3-ANCA and MPO-ANCA) as the primary testing method when AAV is suspected, as recommended by the EULAR/ERA-EDTA guidelines 4
The c-ANCA/PR3 combination has 99% specificity and 73% sensitivity in active systemic disease, but sensitivity drops to 50% in limited forms of disease 3

Rather than relying on ANCA levels, use structured clinical assessment tools such as the Birmingham Vasculitis Activity Score (BVAS) or Vasculitis Damage Index at each visit, as recommended by the EULAR/ERA-EDTA guidelines 3, 5
Essential monitoring parameters include urinalysis at every visit, inflammatory markers (ESR, CRP) and renal function, complete blood count and liver function, and blood glucose monitoring while on glucocorticoid therapy 1, 3, 5, 6

The American College of Rheumatology and the European League Against Rheumatism recommend that treatment changes in AAV should be based on clinical assessment, urinalysis findings, inflammatory markers, and renal function, rather than ANCA testing results 1, 2, 4
The EULAR/ERA-EDTA guidelines state that ANCA testing should not drive treatment decisions, and that clinical assessment should guide treatment changes in AAV patients 1, 2, 4